NRT6003 not checked
Chengdu New Radiomedicine Technology Co. LTD. · Yttrium-90 carbon microspheres
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Patients will be administered NRT6003 Injection via Intra-arterial infusion, and subsequently they will be assessed by PET/CT imaging within 24 hours for its distribution in the chest and upper abdomen, including extrahepatic shunts, intrahepatic distribution, and target lesion distribution as expected.”In the company’s words, NCT06900543 on ClinicalTrials.gov
- Tested for
- Unresectable Hepatocellular Carcinoma
- Main trialPhase 3
- “The goal of this clinical trial is to evaluate the efficacy and safety of NRT6003 Injection compared to cTACE in patients with unresectable HCC.”In the company’s words, NCT06900543 on ClinicalTrials.gov
- Other names
- Yttrium-90 carbon microspheres
Other drugs for Unresectable Hepatocellular Carcinoma
- CadonilimabAkeso · Phase 3
- DurvalumabAstraZeneca · Phase 3
- TremelimumabAstraZeneca · Phase 3
- BudigalimabAbbVie · Phase 2/3
- LivmoniplimabAbbVie · Phase 2/3
- BGB-B2033BeOne Medicines (BeiGene) · Phase 3
Coming up1
- Oct 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Oct 2027 | Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere | |
| Phase 1Completed | 10 Jun 2025 | Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026